Skip Header

You are using a version of browser that may not display all the features of this website. Please consider upgrading your browser.

Germline mutations of inhibins in early-onset ovarian epithelial tumors.

Tournier I., Marlin R., Walton K., Charbonnier F., Coutant S., Thery J.C., Charbonnier C., Spurrell C., Vezain M., Ippolito L., Bougeard G., Roman H., Tinat J., Sabourin J.C., Stoppa-Lyonnet D., Caron O., Bressac-de Paillerets B., Vaur D., King M.C., Harrison C., Frebourg T.

To identify novel genetic bases of early-onset epithelial ovarian tumors, we used the trio exome sequencing strategy in a patient without familial history of cancer who presented metastatic serous ovarian adenocarcinomas at 21 years of age. We identified a single de novo mutation (c.1157A>G/p.Asn386Ser) within the INHBA gene encoding the βA-subunit of inhibins/activins, which play a key role in ovarian development. In vitro, this mutation alters the ratio of secreted activins and inhibins. In a second patient with early-onset serous borderline papillary cystadenoma, we identified an unreported germline mutation (c.179G>T/p.Arg60Leu) of the INHA gene encoding the α-subunit, the partner of the βA-subunit. This mutation also alters the secreted activin/inhibin ratio, by disrupting both inhibin A and inhibin B biosynthesis. In a cohort of 62 cases, we detected an additional unreported germline mutation of the INHBA gene (c.839G>A/p.Gly280Glu). Our results strongly suggest that inhibin mutations contribute to the genetic determinism of epithelial ovarian tumors.

Hum. Mutat. 35:294-297(2014) [PubMed] [Europe PMC]

UniProt is an ELIXIR core data resource
Main funding by: National Institutes of Health

We'd like to inform you that we have updated our Privacy Notice to comply with Europe’s new General Data Protection Regulation (GDPR) that applies since 25 May 2018.

Do not show this banner again